Possible cross-regulation of the E prostanoid receptors

Molecular Carcinogenesis

Volumn 46, Issue 8, 2007, Pages 711-715

  Tober, Kathleen L ^a   Thomas Ahner, Jennifer M ^a   Maruyama, Takayuki ^b   Oberyszyn, Tatiana M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Inflammation; Prostaglandins; Skin cancer

Indexed keywords

ACETONE; BETA 2 ADRENERGIC RECEPTOR; CALCIUM; CELECOXIB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; MYELOPEROXIDASE; ONO 8713; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1 RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN E3 RECEPTOR; PROSTAGLANDIN E4 RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTANOID RECEPTOR; PROTEIN KINASE C; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CONFERENCE PAPER; EPIDERMIS; HUMAN; KERATINOCYTE; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; SKIN CANCER; SKIN CARCINOGENESIS; SKIN INFLAMMATION; TISSUE DISTRIBUTION; ULTRAVIOLET B RADIATION;

ANIMALS; HUMANS; PROSTAGLANDINS; RECEPTORS, PROSTAGLANDIN E; SKIN NEOPLASMS;

MURINAE; MUS;

EID: 34547880425     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20347     Document Type: Conference Paper

References (22)

1. An KP, Athar M, Tang X, et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 2002;76:73-80.
2. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999;25:231-240.
3. Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyszyn TM. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinog 2003;38:49-58.
4. Wilgus TA, Koki AT, Zweifel BS, Rubal PA, Oberyszyn TM. Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer. Mol Carcinog 2003;38:33-39.
5. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
6. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: Subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:661-690.
7. Konger RL, Billings SD, Thompson AB, et al. Immunolocalization of low-affinity prostaglandin E receptors, EP and EP, in adult human epidermis. J Invest Dermatol 2005;124:965-970.
8. Konger RL, Brouxhon S, Partillo S, VanBuskirk J, Pentland AP. The EP3 receptor stimulates ceramide and diacylglycerol release and inhibits growth of primary keratinocytes. Exp Dermatol 2005;14:914-922.
9. Konger RL, Malaviya R, Pentland AP. Growth regulation of primary human keratinocytes by prostaglandin E receptor EP2 and EP3 subtypes. Biochim Biophys Acta 1998;1401:221-234.
10. Tober KL, Thomas-Ahner JM, Kusewitt DF, Oberyszyn TM. Effects of UVB on E prostanoid receptor expression in murine skin. J Invest Dermatol 2007;127:214-221.
11. Claudino RF, Kassuya CA, Ferreira J, Calixto JB. Pharmacological and molecular characterization of the mechanisms involved in prostaglandin E2-induced mouse paw edema. J Pharmacol Exp Ther 2006;318:611-618.
12. Watanabe K, Kawamori T, Nakatsugi S, et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 1999;59:5093-5096.
13. Ma X, Kundu N, Rifat S, Walser T, Fulton AM. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 2006;66:2923-2927.
14. Sung YM, He G, Fischer SM. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res 2005;65:9304-9311.
15. Brouxhon S, Konger RL, VanBuskirk J, et al. Deletion of prostaglandin E2 EP2 receptor protects against ultraviolet-induced carcinogenesis, but increases tumor aggressiveness. J Invest Dermatol 2007;127:439-446.
16. Thompson EJ, Gupta A, Vielhauer GA, Regan JW, Bowden GT. The growth of malignant keratinocytes depends on signaling through the PGE(2) receptor EP1. Neoplasia 2001;3:402-410.
17. Tober KL, Wilgus TA, Kusewitt DF, Thomas-Ahner JM, Maruyama T, Oberyszyn TM. Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development. J Invest Dermatol 2006;126:205-211.
18. Prinster SC, Hague C, Hall RA. Heterodimerization of g protein-coupled receptors: Specificity and functional significance. Pharmacol Rev 2005;57:289-298.
19. McGraw DW, Mihlbachler KA, Schwarb MR, et al. Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J Clin Invest 2006;116:1400-1409.
20. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A. Cell communication networks: Epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 2001;20:1594-1600.
21. Venkatakrishnan G, Exton JH. Identification of determinants in the alpha-subunit of Gq required for phospholipase C activation. J Biol Chem 1996;271:5066-5072.
22. Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 2005;280:24053-24063.